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Abstract
Objectives: The pathogeneses of chronic tension-type
headache (CTTH) and cervicogenic headache (CEH) are
not well established. Peripheral activation or sensitization
of myofascial nociceptors is suggested as a potential
mechanism and injections of botulinum toxin (BONTA)
have thus been used in the treatment for both headache
conditions. BONTA inhibits the release of acetylcholine at
the neuromuscular junction and inhibits contraction of
skeletal muscles. If the pain is precipitated by increased
tone in cervical muscles, local injections of BONTA could
represent a prophylactic measure. However, the treatment
is still controversial, and a thorough assessment of the
current evidence is required. This review aims to assess the
evidence of BONTA injection as a prophylactic treatment
for CTTH and CEH by reviewing and examining the quality
of placebo-controlled, randomized trials.
Methods: Data sources: we searched in the following
databases: PubMed (including Medline), Embase,
Cochrane Central register of Controlled Trials, Cinahl,
Amed, SCOPUS and Google Scholar including other re-
pository sources. BothMeSH and free keywords were used
in conducting the systematic search in the databases. The
search covered publications from the root of the data-
bases to November 2020.
Study eligibility criteria: The review included RCTs,
comparing single treatment of BONTA with placebo on
patients with CTTH or CEH above 18 years of age, by
measuring pain severity/relief or headache frequency.
Data extraction: The following data were extracted: year
of publication, country, setting, trial design, number of
participants, injection procedure, BONTA dosages, and
clinical outcome measures.
Study appraisal: To assess validity and quality, and risk of
bias, the Oxford Pain Validity Scale, Modified Jadad Scale,
last version of Cochrane Collaboration’s tool for assessing
risk of bias (RoB 2), and the CONSORT 2010 Checklist were
used. The trials were assessed, and quality scored inde-
pendently by two of the reviewers. A quantitative synthesis
and meta-analyses of headache frequency and intensity
were performed.
Results: We extracted 16 trials, 12 on prophylactic BONTA
treatment for CTTH and four on CEH. Of these 12 trials (8 on
CTTH and 4 on CEH) were included in the quantitative
synthesis. A majority of the trials found no significant
difference on the primary outcome measure when BONTA
treatment was compared with placebo. Three “positive”
trials, reporting significant difference in favor of BONTA
treatment, but two of these were hampered by low validity
and quality scores and high risk of bias.
Conclusions: There is no clear clinical evidence support-
ing prophylactic treatment with BONTA for CTTH or CEH.
Keywords: botulinum toxin A; chronic tension-type
headache; cervicogenic headache; injection; systematic
review.
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Introduction
Headache is one of the most costly health problems [1].
Chronic tension-type headache (CTTH) is characterized by
bilateral headache ≥15 days a month and has a 1-year
period prevalence of 2.2% [2]. CEH is characterized by a
unilateral headache and the prevalence of cervicogenic
headache (CEH), is less frequent, but affects about 15% of
patients with a chronic headache [3–5]. Both types of
headache account for high rates of disability [4, 6].
The underlying pathophysiology of these two types of
headache is not well established [7, 8]. Tension-type
headache has for years been explained by nociceptive
input from muscular tender or trigger points (MTrP’s) [9],
due to a disturbed function of the neuromuscular endplate
and exaggerated muscular depolarization with contrac-
tions, compressing the small vessels and thereby leading to
muscular ischemia [10]. This explanation has later been
challenged [11, 12]. Psychological conditions like anxiety,
depression [13, 14] and stress [15] seem to play an important
role, and experimental research indicates a sensitization of
sensory pathways and disturbed pain regulation [16],
possibly mediated by serotonergic [17], cholinergic [18],
and inflammatory mechanisms [19, 20]. CEH is by the In-
ternational Headache Society (IHS) defined as a secondary
disorder where cervical spine components like spinal
vertebrae, intervertebral discs and soft tissue elements [21,
22], and musculoskeletal dysfunction are believed to play
an important role [23–25].
Both CTTH and CEH are conditions difficult to treat.
Botulinum toxin A (BONTA) is used clinically for several
conditions, including migraine [26], but for CTTH and CEH
the treatment has been based on the notion of a disturbed
neuromuscular function [27]. The compound blocks the
release of acetylcholine at the neuromuscular junction and
may partially paralyze muscles for a fewmonths [28–31]. A
systematic review and meta-analysis published in 2012,
focused on BONTA treatment for episodic and chronic
migraine, chronic daily headache and CTTH [32]. In this
review CTTH BONTAwas not associated with fewer attacks
permonth. Twomore recent reviews, including low quality
studies like non-controlled trials and prospective aswell as
retrospective cohort studies, however, concluded that
botulinum toxin seems to be effective in the management
of CTTH [33, 34]. The evidence for BONTA treatment for CEH
is limited and in a review, published in 2002 [35], only one
randomized controlled trial [36] and a case study [37] were
identified, and the results were contradictory. Thus, there
is a need for an update on the clinical evidence of BONTA
treatment for CTTH and CEH, which is based on high-
quality studies.
Aims
This systematic review and meta-analysis are limited to
placebo-controlled, randomized trials studying the effi-
cacy and safety of BONTA as prophylactic treatment of
CTTH and CEH. Our aim was to examine and rank the
quality, validity, and risk of bias of the trials in order to
critically assess the clinical evidence of one session with
BONTA injections as a prophylactic treatment for CTTH and
CEH. Ethical approval was not required for a review of
selected publications.
Methods
Criteria for considering trials relevant for this review
A well-focused question based on the PICO1 framework was formu-
lated in order to ensure the identification of appropriate search terms
for finding relevant literature-evidence in writing this systematic re-
view [38, 39]. The standard PICO terms, herein, were translated as
follows:
Type of participants (Population): adult humans with tension-
type headache or cervicogenic headache. Type of interventions
(Intervention): local intramuscular injections including muscular
trigger points (MTrP) with botulinum toxin A. Control/Comparison:
placebo. Type of outcome measures (Outcome): reduced frequency
(days with headache) or reduced headache severity (pain intensity or
pain relief). Based on the PICO terms as indicated above, the search
questions formulated was as follows: in adult humans with tension-
type headache or cervicogenic headache, are local intramuscular in-
jections (includingMTrP) with botulinum toxin-A superior in reducing
days with headache or headache severity (pain relief) compared to
placebo?
Search methods for identification of studies
A systematic search strategy, developed by the physicians at the
University Hospital of Northern Norway (UNN), Tromsø and at the
Finnmark Hospital Trust, Alta, in corroboration with the Senior In-
formation Specialist at theMedical Library of UiT TheArctic University
of Norway and another librarian from the Unit for Applied Clinical
Research - Norwegian University of Science and Technology, was
conducted to identify relevant studies for this systematic review. The
systematic searches were repeatedly conducted until November 2020
using electronic databases PubMed, Embase, Cinahl, Amed, Cochrane
Central Register of Controlled Trials, and SCOPUS. Besides, reference
lists of systematic reviews and included articles were manually
scanned to expand the data set. The final searches were not restricted
on language or publication date, but conducted to up-to-date 03
November 2020. The search strategy was based on the following key
1 The acronym “PICO” stands for P, Population (who/what); I, Inter-
vention (How); C, Control/Comparison (What is the main alternative);
O, Outcome (What are we trying to measure).
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concepts: tension-type headache or cervicogenic headache, Botuli-
num toxin, reducing headache frequency i.e. days with headache or
reducing headache severity. An example of the search strategy, where
bothMeSHand free keywordswere used, as applied inPubMed, canbe
viewed as follows:
((((((tension headache) OR (Tension-Type Headache)) OR
(headache disorders, secondary)) OR (cervicogenic headache)) OR
(cervical)) AND (((((Botulinum Toxins) OR (botulinum)) OR (botuli-
num toxin)) OR (toxin)) OR (toxins))) AND (((((((reduced headache) OR
(headache)) OR (reduced headache severity)) OR (severity)) OR (pain
relief)) OR (reduced headache days)) OR (headache free days)) Filters:
Clinical Trial, Randomized Controlled Trial, Humans.
Besides, a step by step search strategy table can be viewed in
Supplementary Appendix 1 among the e components.
Google Scholar was also searched for triangulation purposes, i.e.
to ensure the identification of all relevant evidence available on the
herein topic and the websites searched, using the reference list of
identified studies. The primary author of one publication was con-
tacted for further information.
We additionally searched for ongoing or recently completed and
unpublished studies through other repository sources such as, www.
clinicaltrials.gov, https://papas.cochrane.org/, http://www.isrctn.
com/ and https://www.crd.york.ac.uk/prospero/. However, none of
the identified articles/trials in the latter registers were found eligible
either due to double registration or because they were not completed
such that results were not available.
Selection criteria for identification of eligible studies
The selection of eligible trials, included in this systematic review, was
conducted in accordance with the PRISMA statement guidelines [40,
41], and developed in close collaboration with the two librarians. The
potentially eligible trials selected were assessed on the efficacy of
BONTA. To assess this, only prospective, placebo-controlled trial,
involving patients of ≥18 years old and with CTTH or CEH, receiving
BONTA injections in selected skeletal muscles in the upper quarter of
the body; and assessed by outcomes on pain severity/pain relief and
number of headache (or headache-free) days per week(s) or month,
were included. The BONTA treatment could be combined with phys-
iotherapy as well as prophylactic and analgesic medications. How-
ever, trials, including patients with neurological diseases (dystonia,
torticollis) or other pain conditions (such as temporomandibular dis-
order or phantom limb pain), were excluded. Only full text available
trial reports were selected for inclusion. The publications subjected to
multiple registration across or within databases, were excluded.
Screening and data extraction for analysis
Screening by trial headings and abstracts of potentially relevant trials
was conducted independently by two of the four authors (SBR and
GK). Full text copies of potentially relevant trials were retrieved and
independently read and reassessed manually by the same authors.
Discrepancy about eligibility was discussed until agreement was
achieved. The bibliographies of the retrieved eligible articles and
systematic reviews were further checked for additional references.
Data extraction from the relevant included trialswasperformed and
was comprised of the following: year of publication, country of origin,
setting, trial design, number of participants, subject characteristics,
information about the intervention procedure, BONTA dosages, and
clinical outcome measures.
Assessment of validity, quality and risk of bias
Each trial underwent a critical assessment by validated assessment
tools such as validity, quality and risk of bias. The scores were
compared, and discrepancies resolved by discussion between the two
authors herein (SBR and GK).
The Oxford Pain Validity Scale for randomized trials (OPVS)
covers five items: blinding, sample size of each trial group, outcomes,
and demonstration of internal sensitivity [42, 43]. The last, main item
includes four sub-items: definition of outcomes, data presentation,
statistical testing, and handling of dropouts. With a total of eight
criteria the score ranges from 0 to16 points [44].
The Modified Jadad Scale consists of five items derived from the
Oxford quality scale [40] focusing on randomization, blinding, with-
drawals and dropouts and three extra items on criteria for eligibility, and
methods to assess adverse events and statistical analysis. The sum score
ranges from 0 to 8 points. The quality scale has shown a good interrater
agreement with an intraclass correlation coefficient at 0.9 [41].
Study quality was also assessed by the number of confirmative
responses to the CONSORT 2010 Checklist (CONsolidated Standards of
reporting trials = CCL-25). The list focuses on how the trial is designed,
analyzed, and results are interpreted and includes 25 items. As some
items include sub-items, it provides a set of 37 yes or no responses
depending on whether the item is reported or not. The checklist is
designed for planning trials [45], and not a quality assessment tool per
se. However, the number of responses provides a thorough consider-
ation of several quality related study characteristics, and several
journals have adopted the checklist in their evaluation of papers in
order to increase the number of high-quality reports, improve RCT
interpretation, and to minimize biased conclusions [46].
With an overlap of items between the different scoring systems,
we found a close correlation between the scores of OPVS andModified
Jadad (Spearman correlation, N: 15, rho: 0.79, p<0.001) and CCL-25
(Spearman correlation, N:15, rho: 0.67, p<0.006)
Risk of bias was assessed for the individual trial by the revised
Cochrane Collaboration’s tools for assessing risk of bias (RoB 2) [47,
48]. The RoB 2 tools are derived from the original Cochrane risk-of-bias
tool for randomized trials (ROB 1) either with a parallel or cross-over
design [48, 49] and is structured into a fixed set of domains, focusing
on different aspects of trial design, conduct, and reporting such as
randomization, blinding, differences in baseline levels,measurement,
missing and selection of outcome data (see Supplementray Table 8).
The risk of bias is generated by an algorithm, based on answers to the
signalling questions and is expressed either by ’low’ or ’high’ or by the
intermediate option ’some concern of’ risk of bias.
Sensitivity analyses
Heterogeneity was assessed by I2 statistics, p-values, Q statistics,
degree of freedom and by calculating the influence of each trial on
standardized mean difference (SMD) by excluding one by one in
separate analysis to investigate the influence on the overall results
[50]. To explore potential publication bias we generated Funnel plots
while bias due to small trials was assessed by the Egger regression test
[51]. As the trials were few and test results rely on assumptions, fixed
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effect andMandel–Paule aka empirical Bayes estimatormeta-analysis
were added [52]. Finally, we assessed the impact of potential cova-
riates on the effect size using a meta-regression-based technique and
with robust variance estimation inmeta-regression if dependent effect
sizes from the same study were included [53–56].
Meta-analysis and other statistical analyses
The quantitative synthesis of effect sizes was carried by a statistician
within the team and based on SMD as effect size for the two common
primary outcomes, pain intensity and pain frequency. Both are rec-
ommended and used in most clinical trials on headache. The effect
sizeswere calculated from final frequency [57], mean values or change
from baseline and standard deviations, standard error of the means,
confidence intervals or p-values described in the manuscripts, tables,
or depicted in figures. Median and range were converted to mean and
standard deviation using the method by Wan et al. [58]. The meta-
analysis with tests and plots were generated by the statistical package
Stata version 16 (Stata Corp, College Station, TX, USA) with the user-
developed packages metan, metafunnel, metabias, metareg and
robumeta. To achieve comparable dosages of abobotulinumtoxin A
(Dysport) and onabotulinumtoxin A (Botox) for pooled analyses
across the trials, we converted dosages of abobotulinumtoxin A by a
divisor of 2.5 [59].
Due to skewed data non-parametric tests were applied for other
statistical analyses. For continuous data bivariate correlations were
carried out by the Spearman’s test and group comparisons by
Independent-Samples Kruskal–Wallis Test. For categorical data
comparisons, the Fisher exact test was used. Significance values were
adjusted by the Bonferroni correction for multiple tests. These corre-
lations and group comparisons were performed by the statistical
package IBM SPSS Statistics 26.
Results
Trials included
The database searches identified 360 publications on the
topic botulinum toxin type A treatment of tension-type
headache and cervicogenic headache. By reading titles
and abstracts, 455 publications were excluded due to
inappropriate diagnosis, intervention, design and/or type
of paper, or due to multiple registration within or across
databases, full text not available or because the trial was
not completed (see Figure 1; flow chart). Thus, 16 trials
were finally extracted for the review [36, 59–73]. The trials
were published between 1999 and 2012 with an aim to
study the clinical efficacy/effectiveness (or “beneficial
effect”). Five trials [36, 59, 68, 70, 72] also aimed to assess
safety of BONTA injections. 12 trials included patients
with CTTH [59–70] while four trials included patients with
CEH [36, 71–73] (Figure 2).
Trial design
All the 16 trials were randomized and placebo-controlled
(Table 1). Fourteen were described as double-blinded and
one single-blinded [70]. One trial report on patients with
CEH did neither describe how patients were blinded nor
report any randomization [73], but the primary author
confirmed by mail that the study was randomized. Four-
teen trials had a parallel and two a cross-over design [66,
72]. Two trials were designed with more than two arms and
compared the efficacy of different BONTA dosages [59, 68]
(see Table 1). Two papers [66, 69] also presented results
from an open-labeled extension/long-term study, these
data were not included in the review.
Sample size
The 16 trials represent a total sample of 954 participants,
823 with CTTH and 131 with CEH, and a total of 571 were
assigned to receive BONTA injections. The sample sizes
varied across the trials from8 to 300 patientswith amedian
of 36.5. Only five trials included a total sample of >40
participants [59, 60, 62, 67, 68]. In three CTTH trials more
than 50 participants received BONTA [59, 67, 68], while in
nine trials the number of participants was less than 20 [36,
61, 63, 65, 66, 69–72] (see Table 1). Four trials [59, 65, 67, 72]
performed sample size calculation, but in one trial as a post
hoc analysis [72]. In two trials they did either not achieve
[67] or present [59] the calculated sample size.
Dropouts
Eleven trials reported rates of dropouts, with a range from
0-28% and a median of 6% (see Table 1). Eleven of the 16
Figure 1: Flow chart.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 Roland et al.: Botulinum toxin on tension-type or cervicogenic headache
trials [36, 59, 60, 62, 64, 65, 67–69, 71, 72] explicitly re-
ported the numbers who completed, were excluded and/or
dropped out, but only eight trials explained why the par-
ticipants dropped out. Two trials reported no dropouts [64,
65], while five did not comment on this issue [61, 63, 66, 70,
73]. Only four trials presented a flow chart [59, 65, 69, 72],
showing the numbers being excluded and participants
who dropped out.
Setting
In five of the 16 trials, patients were recruited from a
hospital service [60, 64, 69, 72, 73], and in two from a
private practice or by advertising [62, 71]. Nine trials did
not provide any information of the recruitment process
(see Table 1). Eight trials were, and one seemed to be,
supported by a pharmaceutical company (see Table 2),
and in two trials a pharmaceutical company was or
seemed to be involved in the trial report [59, 72].
Patient characteristics
The diagnostic criteria for being included varied across the
trials, but included patients equal to or above 18 years of
age with the diagnosis CTTH or CEH. In most trials this was
based on the well-defined criteria from IHS published in
either 1988, 1998, 1997 or 2004 (see Table 1 and Supple-
mentary Table 1). TwoCEH trials, however, used the criteria
from the Headache International Study Group (CHISG) and
one [71] included only patients with headache after a cer-
vical whiplash injury. The sample in the latter study may
not be representative for CEH patients in general. Two
CTTH trials aimed to also include patients with episodic
tension-type headache [61, 64], and in the first one, 16 of 21
participants had episodic tension-type headache [61]. In
the other trial [64] the authors decided not to include a
patient with episodic tension-type headache as all the
remaining patients had CTTH. Six trials [36, 59, 60, 62, 68,
72] accepted ≤1 migraine attack a month or if the patient
was able to differentiate fromCTTH and CEH. In three CTTH
trials [59, 66, 68], and in three CEH trials [36, 71, 73] in-
clusion was restricted to patients with a headache history
for at least six months. One trial [69] selected only patients
where myofascial trigger point palpation reproduced the
typical (“concordant”) pain.
Treatment procedure
The injection protocols varied across the trials in terms of
strategy, formulation of and dosages of BONTA, number of
injection sites (see Table 1), and location (see Supple-
mentary Table 3). Eight CTTH trials [59–64, 67, 68] and two
CEH trials [72, 73] used a pre-determined approach where
BONTA was injected into “fixed sites”, and in five of them
with a fixed dose [60–62, 64, 69] (see Table 1). In one trial
[60] the “fixed sites” injections were guided by EMG. The
symptom-evaluated technique (also termed “follow the
pain”) was used in three CTTH trials [65, 66, 69] and in two
CEH trials [36, 71]. In two of these trials [65, 66] the in-
jections were restricted to sites with increased muscular
resistance or local tenderness, while in a third one [69] in
specified myofascial trigger points, which triggered the
characteristic headache. Finally, one trial [70] combined
the two injection strategies. In the trials above, there was
no clear description on how trigger points were identified
and in one trial [36] the authors did not seem to differen-
tiate between tender or trigger points. The median number
of injection sites was eleven (range 4–22) among the CTTH
trials and six (range 5–10) among the CEH trials.
Most CTTH trials applied injections in the neck,
shoulder and pericranial musculature, but in three trials
[61, 64, 66] to only pericranial musculature, and in one to
the frontal muscle [64]. In two of the four CEH trials BONTA
was also injected in pericranial muscles [72, 73] (see Sup-
plementary Table 3).
Two different BONTA formulations were applied; 11
trials applied onabotulinumtoxin A (Botox®) manufac-
tured by Allergan Inc (Allergan Inc., Irvine, CA, USA) and
five trials abobotulinumtoxin A (Dysport®) manufactured
by Ibsen Pharma (Torre Realia, Plaça d’Europa, 41,
08908 L’Hospitalet de Llobregat, Barcelona, Spain) (see
Table 1). Straube et al. [59] referred to a publication on
equivalency between abobotulinumtoxin A and onabotu-
linumtoxin A and argue that 2–3 units of abobotuli-
numtoxin A are equivalent to 1 unit of onabotulinumtoxin
A (Allergan Inc., Irvine, CA, USA) [74, 75].
The total dosages of BONTA varied for onabotuli-
numtoxin A® from 20 to 150U and for abobotulinumtoxin A
from 150 to 500 U. The BONTA dosages varied less across
CEH trials, for onabotulinumtoxin A from 90 to 100 U and
for abobotulinumtoxin A at 150 U. Among trials, reporting
site dosages, they varied from 2 to 40 U for onabotuli-
numtoxin A and from 12 to 30 U for abobotulinumtoxin A.



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10 Roland et al.: Botulinum toxin on tension-type or cervicogenic headache
To define the optimal dosage Silberstein et al. [68] designed
a 6-armed trial and injected BONTA dosages of 50 U, 100 U
and 150 U or placebo into 10 sites in five muscles, while in
two subgroups (BONTA 86Usub and 100Usub) BONTA 86U
and 100U, respectively were injected in three and saline in
two muscle groups.
Concomitant use of analgesics varied largely across
the trials from a strict policy to free allowance for
concomitant medication (see Supplementary Table 2). In
two trials [59, 72] prophylactic medication were dis-
continued six and four weeks before randomization,
respectively, while a third trial [68] requested the partici-
pants to stay on a stable dose of prophylactic headache
medication for at least 3months prior to enrollment, and to
use stable doses throughout the trial. For rescue medica-
tion one trial [68] accepted only over-the-counter medica-
tion, two trials [59, 69] only one single rescue drug, and a
fourth trial only if headache severity reached 3 at a 5-point
scale [60]. One trial excluded patients using analgesics
more than 10 days a month [67]. Although only three trials
explicitly reported no limitation for rescue medication
[61–63], a total of 11 trials seemed to accept use of anal-
gesics as they registered the consumption of or days with
medication [36, 59, 61, 62, 64, 65, 67–70, 72].
Data sampling
All 16 trials used a headache diary to record days with and/
or without headache and/or intensity of the headache
during a pretreatment interval ranging from 2 to 6 weeks
(baseline) and throughout the follow up with intervals
ranging from 2 to 8 weeks (Table 1). In four trials the par-
ticipants were instructed to record one [59, 67], three [69] or
four times a day [62].
Primary and secondary outcome measures
Primary outcomemeasure: Seven of all trials [59, 62, 63, 65,
67, 68, 72] defined one single primary outcome, while three
presented two or three primary outcomes, respectively [64,
69, 70]. The only CEH trial [72], defining a primary outcome
measure, chose moderate to severe headache frequency.
Three CTTH trials [60, 61, 66] and three CEH trials [36, 71,
73] did neither differentiate between primary nor second-
ary outcomes (see Tables 1 and 2). In Supplementary
Tables 4 and 5, primary and secondary variables and
variables not specified, are listed for each trial.
Eight trials [36, 61, 62, 65, 69–71, 73] assessed head-
ache intensity by a visual analogue scale: four by a 4 or
5-point verbal rating scale [59, 66, 67, 72], one [60] by a six-
point numeric rating scale (a part of the Chronic Pain Index
Score), and one [64] with a combined verbal 4-point and
10-point numeric scale (1–10). In one trial [69] the partici-
pants were requested to daily provide a qualitative
assessment of the pain (McGill Pain Questionnaire-SF).
Efficacy
Six CTTH trials [59, 62, 63, 65, 67, 68] with predefined pri-
mary endpoint and two [60, 61] with no primary endpoint
could not find any significant difference between BONTA
and placebo treatment (see Table 2). In the multi-armed
trial by Silberstein [68], four subgroups (50U, 100U,
100USub and 86U) a higher number reported ≥50%
reduction in headache frequency after 90 days (p: 0.0017–
0.024), but after 120 days the difference remained signifi-
cant for only two of the subgroups (100U and 50U).
Notably, placebo treated patients reported a larger increase
in headache-free days after 60 days compared with the
highest dose of BONTA (150U) (p = 0.007). Correspond-
ingly, Rollnik et al. [61] found higher health status scores
(Everyday Life-Questionnaire) among placebo treated pa-
tients after both 1 and 3 months.
Four CTTH trials [64, 66, 69, 70] found BONTA treat-
ment statistically superior to placebo (see Table 2), but the
second one [66] had no primary endpoint. In two of the
trials [64, 69] only one of two primary endpoints was
significantly reduced compared with placebo. The trial by
Hamdy et al. [70] reported significant group differences for
three primary endpoints after 30 and 90 days including
headache days per month (p≤0.005), headache severity
(p≤0.007), and headache disability (p≤0.027).
In two CEH trials [36, 72], one with predefined primary
endpoint, onabotulinumtoxin A was not superior to pla-
cebo. A pilot study [71] reported significant improvement
frombaseline in headache severity and active ROM4weeks
after BONTA treatment of (onabotulinumtoxin A 100 U),
but did not report any statistical comparison to placebo. As
this was a pilot study, they did not conclude on effective-
ness. Thus, only one CEH trial [73] found BONTA superior
to placebo, however, this trial report did neither comment
on randomization nor describe the blinding process.
Quantitative synthesis and meta-analysis
Twelve of the trials were included in the quantitative syn-
thesis and meta-analysis (Figure 2A, B), while four were
excluded due to insufficient outcome data. In the random-
Roland et al.: Botulinum toxin on tension-type or cervicogenic headache 11
effects meta-analyses on pain frequency and pain in-
tensity, there was among the CTTH trials a significant dif-
ference favoring BONTA on pain intensity (SMD −0.35,
95CI −0.70 to −0.002, p-value 0.049), but not on frequency
(SMD −0.34, 95CI −0.71 to 0.02, p-value 0.066). Among the
CEH trails there was a significant effect favoring BONTA on
frequency (SMD −0.74, 95CI −1.42 to −0.06, p-value 0.034)
and on intensity (SMD −0.38, 95CI −0.74 to −0.03, p-value
0.036).
Side effects
Side effects were recorded in eight out of 12 CTTH trials and
in all four CEH trials (see Supplementary Table 9). Among
BONTA treated patients, the rates averaged 31% with a
range from0 to 69%and amongplacebo treated an average
of 15% with a range from 0 to 62%. The most common side
effects weremuscular weakness, headache, and symptoms
from the injection site and neck pain, and they were
generally mild to moderate and transient in nature.
Low to moderate dosages of onabotulinumtoxin A
from 20 U to 150 U [36, 62, 65, 68–73] did not increase the
occurrence of side effects. In a trial with high abobotuli-
numtoxin A dosages (500 units) Schulte-Mattler et al. [67]
observed side effects only in the active group. Straube et al.
[59] correspondingly found a higher proportion of side ef-
fects events after abobotulinumtoxin A 420 units (27%) and
210 units (25%) versus placebo (7%). Dysphagia occurred
in 7% after 420 units of abobotulinumtoxin A versus 2%
after placebo; and ptosis was only observed in patients
receiving 420 units of abobotulinumtoxin A (4%). The
proportions, reporting muscle weakness, increased from
6% at 210 units to 18% with 420 units. In the 6-arm trial by
Silberstein et al. [68], they, contrastingly, found no
consistent dose-response of side effects. In this systematic
review therewas no significant correlation betweenBONTA
dosages and overall number of side effects.
Validity and quality of the trials and risk of
bias
Standardized validity and quality tools provided a detailed
assessment of the trials (see Table 2). Among 11 CTTH trials
the OPVS scores ranged from 5 to 16 with a median score of
10. Among CEH trials the OPVS scores ranged from 7 to 14
with amedian score of 10.5. Five CTTH trials [60, 61, 66, 69,
70] and two CEH trials [73] achieved low OPVS scores <10
due to insufficient information on blinding, small study
samples, dropouts, or no correction for multiple testing
and in one trial due to a single blinded design (see Table 2).
One CTTH trial [63] had a sample size too low to obtain a
validity (OPVS) score. The item specific scores of OPVS are
presented in Supplementary Table 6.
The Modified Jadad quality score of the CTTH trials
ranged from 4 to 7 with a median score of 5.8. For the CEH
trials it ranged from 1 to 8 with a median of 6.5 (see Table 2).
Separate item scores are presented in Supplementary Table 7.
LowModified Jadad scores reflected inadequate reporting on
Figure 2A: Standardized mean difference in
headache frequency between botulinum
toxin A versus placebo in 10 randomized
controlled trials. (A) Forest plot where the
size of datamarkers is proportional to study
weight.
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trial design, lack of information or inappropriate randomi-
zation, concealment of allocation or blinding of intervention,
withdrawals, how dropouts were handled, or method to
assess adverse event described, and for one trial single blin-
ded design. Only five of the trials explicitly described an
appropriate blinding process [62, 64, 68, 71, 72] while in two
trials it was inappropriate [59, 73].
In the supplementary check with the CONSORT
Checklist 25 we counted a median of 21 confirmations
(range 7–26) among the CTTH trials and a median of 15.5
(range 12–30) among the CEH trials (see Table 2).
Six CTTH trials [60, 61, 63, 66, 69, 70] were associated
with high risk of bias,while six trials [59, 62, 64, 65, 67]with
some concerns of risk of bias. Among the four CEH trials,
two [36, 73] were associated with high risk and two [71, 72]
with some concerns of risk of bias (see Table 2). Separate
item scores of the Risk of bias tool (RoB2), describing the
reason for risk of bias, are presented in Supplementary
Table 8.
The validity (OPVS) and quality scores (Modified Jadad
score, Consort Check list 25) were higher in trials with a
negative primary endpoint comparedwith trials with either
a positive or not defined primary endpoint, but the statis-
tical comparisons reached statistical significance only for
the OPVS (Independent-Samples Kruskal–Wallis Test, N:
15, p=0.01), CCL-25 scores, and CCL-25 (Independent-
Samples Kruskal–Wallis Test, N: 16, p=0.034). In pairwise
comparisons with Bonferroni corrections significant
difference was limited to comparisons to those with no
defined primary endpoint (OPVS N:15, p=0.011 and
CCL-25 N: 16: p=0.029). The Fisher exact test, correspond-
ingly, revealed higher proportions of trials with a negative
primary endpoint when OPVS scores were ≥12 (N: 15,
p=0.014), Modified Jadad scores ≥ 6 (N: 16, p=0.031), and
numbers of confirmed CCL-25 items were ≥18 (N: 16,
p=0.02). The proportion of studies with high risk or bias
was also significantly lower among those with a negative
primary endpoint (Fisher exact test: N: 16, p=0.014).
Only four trials (25%) used intention-to-treat anal-
ysis, seven (44%) described an adequate sequence gen-
eration, four (25%) a concealed allocation, and six trials
(38%) an adequate blinding (Supplementary Tables 6
and 7). With Fisher exact test we found a positive rela-
tionship between the negative primary outcome and
blinding (p=0.02), but not to intention-to-treat analysis
(p=0.18), concealed allocation (p=0.769), adequacy of
sequence generation (p=0.205), or proportion of drop-
outs (Independent-Samples Kruskal–Wallis Test. N: 16,
p=0.200).
Sponsorship has been considered a potential source of
bias [76]. We oppositely found a trend towards higher
validity (OPVS) and quality in the trials supported by
pharmaceutical industry. Only one sponsored trial [59]
concluded positively despite negative primary endpoint,
and in this case the company had been involved in editing
the manuscript.
Figure 2B: Standardized mean difference in
pain intensity between botulinum toxin A
versus placebo in 11 randomized controlled
trials. (B) Forest plot based on the endpoint
pain intensity (severity). Two trials (Rollnik
et al. [61] and Schulte-Mattler et al. [67])
used the product of pain intensity and pain
duration (AUC) as endpoint. Size of data
markers is proportional to study weight.
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Sensitivity analyses
The heterogeneity for the outcomes was high among CTTH
and CEH trials (Figure 2), with I2 values of 57.3% (Q=14.05,
p=0.029) and 75.3% (Q=8.11, p=0.017), respectively, for the
frequency outcomes and I2 = 59.9% (Q=15.0, p=0.021) and
30.5% (Q=4.32, p=0.229), respectively, for the intensity
outcomes. One positive CTTH trial [70] and one CEH trial
[73], with particular low study quality, had a substantial
influence on the pooled standardized effect size. The other
trials, however, had no strong influence on the pooled SMD.
Assessing the corresponding funnel plots for headache fre-
quency and headache intensity, and the Egger’s regression
test for small-study effects, no publication bias was found
(p-levels between 0.26 and 0.8). The additional fixed effect
andMandel–Paule empirical Bayes estimatormeta-analysis
showed comparable results with random-effects meta-
analysis (Supplementary Table 10). The meta-regression-
based analysis found no significant relationship between
the primary outcome and age (p=0.331), sample size
(p=0.236), study duration (p=0.484) and dosages (p=0.697),
but significant improved BONTA effect with increased pro-
portion of women (p=0.029) when analyzing all trials
together (Supplementary Table 11). The Meta-analyses
seems robust against biases, but two trials with a strong
positive effect influenced the pooled SMD.
Statistical analyses applied in the reviewed
trials
In most of the trial reports data was described as means
with SD, only one trial used medians [71]. Within- and
between-group comparisons were performed with Stu-
dent’s t-test [60–66, 70] or non-parametric analyses such
as Mann–Whitney U test or Wilcoxon tests [59, 65–68, 73].
Some of the trials applied ANOVA [64], GLM ANOVA
repeated measure [36, 61, 62, 64, 67, 69–71], non-
parametric ANOVA like Kruskal–Wallis Test [68] or Mixed
Linear Models [72]. In six trials between-group compari-
sons of categorical data were carried out with Chi square or
Fisher exact test [62–65, 68, 70] and in one trial the
McNemar test was used for within-group comparisons [72].
In most trials p-values less than 0.05 indicated statis-
tical significance while one trial [68] defined a statistical
p-level of 0.10 for subgroup interaction analyses. One trial
performed Tukey’s Studentized range test [64] and three
Bonferroni corrections [67, 69, 72] with a stricter significant
level for multiple comparisons. Confidence intervals were
presented in three trials [59, 65, 72]. Number needed to treat
analysis were carried out in only one trial [36].
A large number of the trials demonstrated statistical
limitations: Only one trial used ANCOVA to balance for
different baseline levels [69], four trials performed
intention-to-treat-analysis [59, 68, 69, 72] and only two
described how missing values were handled [69, 72]. The
computer program for statistical analyses (SPSS or SAS)
was described in eight of the 14 trials [36, 64, 65, 67, 69–73].
Discussion
This comprehensive systematic review and meta-analysis
cannot confirm a prophylactic effect of botulinum toxin in-
jections or identify any dose-response pattern [59, 68] for
CTTH or CEH. Our findings strongly contrast two recent re-
views, which included non-randomized, prospective and
retrospective cohort studies [33, 34]. BONTA was not supe-
rior to placebo treatment in eight of 12 CTTH trials [59, 61–63,
65, 67, 68], and in three of four CEH trials [36, 72]. Trials with
negative primary endpoint were associated with higher
validity and quality scores compared with trials, favoring
BONTA, which “positive” trials were hampered by low
quality and high risk of bias. Most trials presented a low
standardized mean difference less than 0.5 (see Figure 2),
suggesting no clinically meaningful effect of BONTA [77],
while three trials had a strong positive effect (two with low
quality scores) which explain the slightly positive pooled
SMD in the meta-analyses.
Several causes might explain this low ability to
demonstrate a BONTA effect [72]. BONTAmay be ineffective
for CTTH and CEH, but a pain relieving effect of peripheral
“needling” and saline/local anesthetic injections or
concomitant treatment could also explain the small effect
sizes [59]. In one trial [36] the participants additionally
received physical therapy (massages and hot mud packs)
and in some the trials participants were allowed rescue
analgesia. The “negative” trial by Rollnik et al. [61] included
patients with episodic tension-type headache and a low
headache frequency at baseline (mean 16.2 and SD 10.8)
might have reduced the effect size. Due to small effect size
the trial byPadberg et al. [65]wouldneed800participants to
reach a significant group difference.
Standardized validity and quality tools do not evaluate
the quality of the intervention/injectionprocedure itself. It is
therefore prudent to question whether the treatment pro-
tocols were properly designed in the “negative” trials. None
of the studies used an image-guided technique (X-ray with
contrast agent or ultrasound), and only one applied EMG
guidance to confirm intramuscular needle position [60].
Thus, one could question whether the active component
BONTA reached the neuromuscular junctions. Considering
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that pericranial muscles are located superficially, we find it
more likely that BONTA reached the muscular layer after
pericranial injections.
Different injection techniqueswere applied across the
trials, but the “follow the pain” strategy did not demon-
strate better results compared with “fixed site” injections.
There was a large variation in BONTA dosages across trials
and some have argued that BONTA dosages in some trials
were too small to obtain a clinical meaningful effect. The
phase 3 PREEMPT studies on migraine treatment (PRE-
EMPT= Research EvaluatingMigraine Prophylaxis Therapy)
[26] applied onabotulinumtoxin A dosages of 155 and 195 U,
and in the treatment of dystonia 500 units abobotuli-
numtoxin A have been recommended [78]. The findings by
Straube et al. [59] could support this notion: they reported
better effect of a highdose (420units) abobotulinumtoxinA,
headacheduration, andphysician aswell aspatient’s global
assessmentweremorepronounced comparedwith lowdose
(210 units) abobotulinumtoxin A. On the other hand, they
reported increased proportion of muscle weakness from 6%
at 210 units to 18% at 420 units [59], suggesting that a
tolerable limit had been reached. The large dose ranging
trial by Silberstein et al. [68] could furthermore not confirm
any dose-response of BONTA. After 60 days placebo-treated
patients actually reported a larger increase in headache-free
days compared to patients who had received 150 units
onabotulinumtoxin A.
These higher rates of side effects after BONTA in-
jections might have unblinded participants in some of the
trials. In the “positive” trial by Kokoska [64], which
included patients with frontal CTTH, three BONTA treated
participants reported ptosis vs zero in the placebo group.
The three patients (15% of all BONTA treated) were prob-
ably unblinded, and this may have interfered with the
experienced treatment effect.
The response to saline injections in some of the “nega-
tive” trials indicates a placebo effect, although regression
towards the mean and the Hawthorne effect cannot be
excluded [79]. Placebo responses have been shown in
several headache studies [80, 81], and seem to be even
higher after invasiveprocedures [82]. In that case, it suggests
adequate blinding of these trials. Supporting this, we found
highest validity and quality scores in trials with a negative
primary endpoint, in line with a previous systematic review
and meta-analysis on acupuncture [42]. This phenomenon
clearly illustrates the impact of adequate randomization and
blinding in clinical trials [40, 83], and it is notable when two
recent systematic reviews [33, 34] on BONTA treatment for
CTTH, included low quality, non-randomized and non-
controlled cohort studies.
Strength and limitations of the review
This review followed the current PRISMA recommendations
for systematic reviews and included a large sample of par-
ticipants (898participants)where 535 received BONTA. Eight
of the trials chose pain intensity and/or headache frequency
as primary endpoint. Both endpoints are clinically relevant
and should be sensitive enough to demonstrate a clinically
significant difference. The external validity of these findings
should therefore be satisfactory.
Other researchers have suggested that repeated
injections may increase and prolong the effect of BONTA
[32, 65, 66, 84, 85]. This has so far not been tested in
randomized, placebo-controlled trials, and we do not
have sufficient data to answer this question.
Conclusion
After critically reviewing available data from 16 selected
RCTs with a quantitative synthesis and meta-analyses,
including 11 of the trials, we cannot conclude that pro-
phylactic BONTA injections are superior to placebo treat-
ment for tension-type headache or cervicogenic headache,
irrespective of injection technique and dosage level. Our
findings challenge the notion that increasedmuscular tone
or trigger points are responsible for CTTH and support
previous studies indicating more complex mechanisms.
Also for CEH other mechanisms seem to play a role. To
answer the question about efficacy of BONTA injections,
future reviews should be based on large, well-designed,
randomized, placebo-controlled trials and not non-
controlled studies with low validity and quality and a
high risk of bias.
Clinical implications
After systematically reviewing 16 selected RCTs on BONTA
injection, we cannot recommend prophylactic treatment
with BONTA for tension-type headache or cervicogenic
headache.
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